Literature DB >> 11943214

Leukotactin-1/CCL15-induced chemotaxis signaling through CCR1 in HOS cells.

Jesang Ko1, In Sik Kim, Sung Wuk Jang, Young Han Lee, Soon Young Shin, Do Sik Min, Doe Sun Na.   

Abstract

Leukotactin-1 (Lkn-1)/CCL15 is a recently cloned CC-chemokine that binds to the CCR1 and CCR3. Although Lkn-1 has been known to function as a chemoattractant for neutrophils, monocytes and lymphocytes, its cellular mechanism remains unclear. To understand the mechanism of Lkn-1-induced chemotaxis signaling, we examined the chemotactic activities of human osteogenic sarcoma cells expressing CCR1 in response to Lkn-1 using inhibitors of signaling molecules. Inhibitors of G(i)/G(o) protein, phospholipase C (PLC) and protein kinase Cdelta (PKCdelta) inhibited the chemotactic activity of Lkn-1 indicating that Lkn-1-induced chemotaxis signal is transduced through G(i)/G(o) protein, PLC and PKCdelta. The activities of PLC and PKCdelta were also enhanced by Lkn-1 stimulation. Chemotactic activity of Lkn-1 was inhibited by the treatment of cycloheximide and actinomycin D suggesting that newly synthesized proteins are needed for chemotaxis. Nuclear factor-kappaB (NF-kappaB) inhibitor reduced chemotactic activity of Lkn-1. DNA binding activity of NF-kappaB was also enhanced by Lkn-1 stimulation. These results suggest that Lkn-1 transduces the signal through G(i)/G(o) protein, PLC, PKCdelta, NF-kappaB and newly synthesized proteins for chemotaxis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943214     DOI: 10.1016/s0014-5793(02)02465-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Leukotactin-1/CCL15 induces cell migration and differentiation of human eosinophilic leukemia EoL-1 cells through PKCdelta activation.

Authors:  Ji-Sook Lee; In Sik Kim
Journal:  Mol Biol Rep       Date:  2009-08-11       Impact factor: 2.316

2.  Macrophage inflammatory protein 1alpha inhibits postentry steps of human immunodeficiency virus type 1 infection via suppression of intracellular cyclic AMP.

Authors:  Carol-Ann Amella; Barbara Sherry; David H Shepp; Helena Schmidtmayerova
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Human LZIP induces monocyte CC chemokine receptor 2 expression leading to enhancement of monocyte chemoattractant protein 1/CCL2-induced cell migration.

Authors:  Ho Joong Sung; Yoon Suk Kim; Hyereen Kang; Jesang Ko
Journal:  Exp Mol Med       Date:  2008-06-30       Impact factor: 8.718

4.  Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer.

Authors:  C Bodelon; M Y Polley; T J Kemp; A C Pesatori; L M McShane; N E Caporaso; A Hildesheim; L A Pinto; M T Landi
Journal:  Ann Oncol       Date:  2013-05-16       Impact factor: 32.976

5.  Cell migration to CXCL12 requires simultaneous IKKα and IKKβ-dependent NF-κB signaling.

Authors:  Richard R Kew; Kenneth B Marcu; Marianna Penzo; David M Habiel; Mahalakshmi Ramadass
Journal:  Biochim Biophys Acta       Date:  2014-04-18

6.  CCL15 overexpression predicts poor prognosis for hepatocellular carcinoma.

Authors:  YueGuo Li; Hai Peng Yu; Peng Zhang
Journal:  Hepatol Int       Date:  2015-12-07       Impact factor: 6.047

7.  CCL15/CCR1 axis is involved in hepatocellular carcinoma cells migration and invasion.

Authors:  Yueguo Li; Jing Wu; Peng Zhang
Journal:  Tumour Biol       Date:  2015-10-26

Review 8.  CC-chemokine CCL15 expression and possible implications for the pathogenesis of IgE-related severe asthma.

Authors:  Yasuo Shimizu; Kunio Dobashi
Journal:  Mediators Inflamm       Date:  2012-10-31       Impact factor: 4.711

9.  A complex pattern of chemokine receptor expression is seen in osteosarcoma.

Authors:  Irene von Luettichau; Stephan Segerer; Alexandra Wechselberger; Mike Notohamiprodjo; Michaela Nathrath; Markus Kremer; Anna Henger; Roghieh Djafarzadeh; Stefan Burdach; Ralf Huss; Peter J Nelson
Journal:  BMC Cancer       Date:  2008-01-24       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.